Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches

Content Provider	Semantic Scholar
Author	Braun, Jürgen Sieper, Joachim
Copyright Year	2002
Abstract	Therapeutic options for patients with more severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is accumulating evidence that anti-tumor-necrosis-factor (anti-TNF) therapy is highly effective in SpA, especially in ankylosing spondylitis and psoriatic arthritis. The major anti-TNF-alpha agents currently available, infliximab (Remicade(R)) and etanercept (Enbrel(R)), are approved for the treatment of rheumatoid arthritis (RA) in many countries. In ankylosing spondylitis there is an unmet medical need, since there are almost no disease-modifying antirheumatic drugs (DMARDs) available for severely affected patients, especially those with spinal manifestations. Judging from recent data from more than 300 patients with SpA, anti-TNF therapy seems to be even more effective in SpA than in rheumatoid arthritis. However, it remains to be shown whether patients benefit from long-term treatment, whether radiological progression and ankylosis can be stopped and whether long-term biologic therapy is safe.
Starting Page	307
Ending Page	321
Page Count	15
File Format	PDF HTM / HTML
PubMed reference number	12223105v1
Volume Number	4
Journal	Arthritis research
Alternate Webpage(s)	https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar592?site=arthritis-research.biomedcentral.com
Alternate Webpage(s)	http://www2.courses.vcu.edu/ptxed/as/download/AS%20Rx%20Arth%20Res%202002.pdf
Language	English
Access Restriction	Open
Subject Keyword	Ankylosing spondylitis Antirheumatic Agents Arthritis, Psoriatic Etanercept Necrosis Neoplasms Patients Rheumatoid Arthritis Spondylarthritis infliximab
Content Type	Text
Resource Type	Article